• Something wrong with this record ?

Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation

A. Caliò, JN. Eble, O. Hes, G. Martignoni, SE. Harari, SR. Williamson, M. Brunelli, AO. Osunkoya, L. Wang, E. Comperat, A. Lopez-Beltran, M. Wang, S. Zhang, KL. Curless, KM. Post, HY. Chang, C. Luchini, LA. Baldrige, GT. MacLennan, R. Montironi,...

. 2017 ; 8 (33) : 54096-54105. [pub] 20160808

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc17031953

BRAF mutation recently has been reported in metanephric adenoma. We sought to determine the clinical and morphologic features of BRAF-mutated metanephric adenoma and to correlate BRAF mutation with BRAF V600E immunohistochemical staining results. A series of 48 metanephric adenomas and 15 epithelial-predominant nephroblastomas were analyzed for the occurrence of BRAF mutation (BRAF V600E/V600E complex, BRAF V600D, BRAF V600K and BRAF V600R) using the BRAF RGQ PCR kit (Qiagen). Immunohistochemistry was performed using monoclonal mouse antibodies against p16(INK4) and VE1 (Spring Bioscience), recognizing the BRAF V600E mutant protein. Forty-one of 48 cases (85%) showed BRAF V600E mutation; none of the other BRAF variants was detected. Of 41 BRAF-mutated metanephric adenomas, 33 showed positive VE1 immunostaining (sensitivity 80%, specificity 100%); in all cases we detected p16(INK4) expression regardless of BRAF mutation status. All epithelial-predominant nephroblastomas were BRAF-wild-type and none expressed VE1. The following features were associated with BRAF V600E mutation: older patients (p=0.01), female predominance (p=0.005) and the presence of a predominantly acinar architecture (p=0.003). In summary, BRAF-mutated metanephric adenomas were associated with older age, female predominance, and the presence of a predominant acinar component. A subset (20%) of BRAF-mutated metanephric adenomas was not detected by VE1 immunostaining.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17031953
003      
CZ-PrNML
005      
20201019102659.0
007      
ta
008      
171025s2017 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.11117 $2 doi
035    __
$a (PubMed)28903326
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Caliò, Anna $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Department of Pathology, University of Verona, Verona, Italy.
245    10
$a Distinct clinicopathological features in metanephric adenoma harboring BRAF mutation / $c A. Caliò, JN. Eble, O. Hes, G. Martignoni, SE. Harari, SR. Williamson, M. Brunelli, AO. Osunkoya, L. Wang, E. Comperat, A. Lopez-Beltran, M. Wang, S. Zhang, KL. Curless, KM. Post, HY. Chang, C. Luchini, LA. Baldrige, GT. MacLennan, R. Montironi, DJ. Grignon, L. Cheng,
520    9_
$a BRAF mutation recently has been reported in metanephric adenoma. We sought to determine the clinical and morphologic features of BRAF-mutated metanephric adenoma and to correlate BRAF mutation with BRAF V600E immunohistochemical staining results. A series of 48 metanephric adenomas and 15 epithelial-predominant nephroblastomas were analyzed for the occurrence of BRAF mutation (BRAF V600E/V600E complex, BRAF V600D, BRAF V600K and BRAF V600R) using the BRAF RGQ PCR kit (Qiagen). Immunohistochemistry was performed using monoclonal mouse antibodies against p16(INK4) and VE1 (Spring Bioscience), recognizing the BRAF V600E mutant protein. Forty-one of 48 cases (85%) showed BRAF V600E mutation; none of the other BRAF variants was detected. Of 41 BRAF-mutated metanephric adenomas, 33 showed positive VE1 immunostaining (sensitivity 80%, specificity 100%); in all cases we detected p16(INK4) expression regardless of BRAF mutation status. All epithelial-predominant nephroblastomas were BRAF-wild-type and none expressed VE1. The following features were associated with BRAF V600E mutation: older patients (p=0.01), female predominance (p=0.005) and the presence of a predominantly acinar architecture (p=0.003). In summary, BRAF-mutated metanephric adenomas were associated with older age, female predominance, and the presence of a predominant acinar component. A subset (20%) of BRAF-mutated metanephric adenomas was not detected by VE1 immunostaining.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Eble, John N $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Hes, Ondrej $u Department of Pathology, Charles University Hospital Plzeň, Pilsen, Czech Republic.
700    1_
$a Martignoni, Guido $u Department of Pathology, University of Verona, Verona, Italy. Department of Pathology, Pederzoli Hospital, Peschiera, Italy.
700    1_
$a Harari, Saul E $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Williamson, Sean R $u Department of Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, Michigan, USA.
700    1_
$a Brunelli, Matteo $u Department of Pathology, University of Verona, Verona, Italy.
700    1_
$a Osunkoya, Adeboye O $u Department of Pathology, Emory University School of Medicine, Atlanta, Georgia, USA.
700    1_
$a Wang, Lisha $u Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, Michigan, USA.
700    1_
$a Comperat, Eva $u Department of Pathology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.
700    1_
$a Lopez-Beltran, Antonio $u Unit of Anatomical Pathology, Department of Surgery, Faculty of Medicine, Cordoba, Spain and Champalimaud Clinical Center, Lisbon, Portugal.
700    1_
$a Wang, Mingsheng $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Zhang, Shaobo $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Curless, Kendra L $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Post, Kristin M $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Chang, Hsim-Yee $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Luchini, Claudio $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Department of Pathology, University of Verona, Verona, Italy.
700    1_
$a Baldrige, Lee Ann $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a MacLennan, Gregory T $u Departments of Pathology and Laboratory Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
700    1_
$a Montironi, Rodolfo $u Department of Pathological Anatomy and Histopathology, School of Medicine, Polytechnic University of The Marche Region (Ancona), Ancona, Italy.
700    1_
$a Grignon, David J., $d -2020 $7 xx0252915 $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
700    1_
$a Cheng, Liang $u Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 8, č. 33 (2017), s. 54096-54105
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28903326 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20171025 $b ABA008
991    __
$a 20201019102634 $b ABA008
999    __
$a ind $b bmc $g 1255546 $s 992980
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 8 $c 33 $d 54096-54105 $e 20160808 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20171025

Find record

Citation metrics

Archiving options